Preview

May 2019

In the next issue of Pharma Technology Focus, we explore the potential of ketamine-based products following the US FDA’s vote to back Johnson & Johnson’s depression drug esketamine and track the life and times of the European Medicines Agency as the flag goes down on the organisation’s London headquarters.


We also examine the launch of Australian medical cannabis firm Althea in the UK and find out what the pharma and biotech industries could learn from an open-science approach to drug development


Plus, we take a look at the research from Toronto's Centre for Addiction and Mental Health and examine other treatments targeting memory loss. Finally, we speak to the team behind RUNLABS, a start-up dedicated to providing laboratory space and accelerator services to new biotech firm, to find out what services these fledgling businesses need during their early years.

EDITORIAL

Editor | Eloise McLennan

Group Editor | Susanne Hauner

Commissioning Editor | Daniel Garrun

Writers | Abi Millar, Charlotte Edwards, Chris Lo, Allie Nawrat, Sally Turner, Catherine Gambert
Magazine Designer | Marzia Del Gaone

Graphic Designers | Paulius Zutautas, Kate Cuntapay, Anett Arc, Sara Basto, Ashley McPherson, Tyrrell Lowe, Noemi Balint
Lead Designer | John Hammond 
Digital Publishing Director | Duncan West

Advertising

Sales Manager | Nimai Amin

+44 (0) 207 936 6453

Marketing

Media Partnership Enquiries | Susanne Hauner

Pharma Technology focus is powered by h5mag

read past issues of pharma technology focus HERE

Pharma Technology Focus is a product of Net Resources International. Copyright 2018 Net Resources International, a trading division of Kable Intelligence Limited. Registered office John Carpenter House, John Carpenter Street, London, EC4Y 0AN, UK. Company registration number 03171601. All rights reserved. No part of this publication may be reproduced in any form or by any means, electronic, photocopying or otherwise, without prior permission of the publisher and copyright owner. While every effort has been made to ensure the accuracy of this publication, the publisher accepts no responsibility for errors or omissions. The products and services advertised are those of individual authors and are not necessarily endorsed by or connected with the publisher. The opinions expressed in the articles within this publication are those of individual authors and not necessarily those of the publisher.

Go to article: Home | The absence of antivenomGo to article: In this issueGo to article: Daiichi JitsugyoGo to article: ContentsGo to article: Capsugel Company InsightGo to article: CapsugelGo to article: NewsGo to article: Scandinavian Health Ltd.Go to article: International Cannabis and Cannabinoid Institute (ICCI) Company InsightGo to article: International Cannabis and Cannabinoid Institute (ICCI)Go to article: The pharma industry briefingGo to article: TSS Company InsightGo to article: TSS ABGo to article: Action Medical Research: celebrating decades of discovery Go to article: Swiss WorldCargoGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Moehs Iberica SLGo to article: Owen MumfordGo to article: How government policy has shaped China’s pharma phenomenonGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Novo NordiskGo to article: Snake venom in pharma; access to antivenom is a topic that needs attentionGo to article: Phoenix Group Company InsightGo to article: Phoenix Group Go to article: ME Logistic ServicesGo to article: Discussing drug policy reform with psychedelics campaigner Amanda FeildingGo to article: Finnair Cargo | Company InsightGo to article: Finnair CargoGo to article: Aseptic TechnologiesGo to article: False flags: are search engines benefiting rogue online pharmacies?Go to article: CBDepot Company InsightGo to article: CBDepotGo to article: Wilco Company Insight Go to article: WilcoGo to article: The Mighty: how patients and pharma align in the age of social media Go to article: Pharma Support Services Company InsightGo to article: Pharma Support ServicesGo to article: MicronovaGo to article: Inside Italy’s pharmaceutical industry Go to article: KlingeGo to article: BEAGo to article: Erdmann Design SwitzerlandGo to article: Inside the UK’s first vaccines innovation centreGo to article: AralabGo to article: Applikon BiotechnologyGo to article: BaxterGo to article: NymiGo to article: Fostering closer collaboration between manufacturing & regulatory functionsGo to article: EmisphereGo to article: SephaGo to article: Contract Pharmaceuticals Limited CanadaGo to article: EventsGo to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Next issueGo to article: PolpharmaGo to article: BioAdvice